Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark Office

Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin
Dosing by U.S. Patent and Trademark Office 


KING OF PRUSSIA, Penn., June 2  /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that the
United States Patent and Trademark Office issued patent number 6,900,175
entitled "Methods of Administrating Dalbavancin For Treatment Of Bacterial
Infections."  The patent, which will expire in December 2023, relates to a
novel dosing regimen for dalbavancin.  The dalbavancin New Drug Application
(NDA) for the treatment of complicated skin and soft tissue infections (cSSTIs)
including the most difficult to treat strain of staphylococcus,
methicillin-resistant staphylococcus aureus (MRSA) is currently under review
with the U.S. Food and Drug Administration (FDA).

About Dalbavancin

Dalbavancin is a novel second-generation lipoglycopeptide agent that belongs to
the same class as vancomycin. Vancomycin is one of the few treatments available
to hospital patients infected with difficult-to-treat strains of Staphylococcus
bacteria, or Staph known as MRSA (methicillin- resistant Staphylococcus aureus)
and MRSE (methicillin-resistant Staphylococcus epidermidis). Dalbavancin has
been specifically designed as an improved alternative to vancomycin.

About Vicuron Pharmaceuticals

Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. The company has two New Drug Applications pending with the U.S. Food
and Drug Administration for its lead products, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent.  Vicuron's versatile research engine
integrates industry-leading expertise in functional genomics, mechanism-based
drug design and combinatorial and medicinal chemistry.  These approaches are
yielding promising novel and next-generation compounds, many of which are in
the later stages of preclinical development. In addition, the company has
research collaborations with leading pharmaceutical companies, such as Pfizer.

Forward-Looking Statements

This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed or
unsuccessful, that the timing of the filing of any new drug application or any
amendment to a new drug application might be delayed, that clinical trials
might indicate that a product candidate is unsafe or ineffective, that the FDA
might require additional information to be submitted and additional actions to
be taken before it will make any decision, that any filed new drug application
may not be approved by the FDA, that ongoing proprietary and collaborative
research might not occur or yield useful results, that the pipeline may not
yield a new clinical candidate or a commercial product, that a third party may
not be willing to license product candidates on terms acceptable to us or at
all, that competitors might develop superior substitutes for Vicuron's products
or market these competitive products more effectively, that a sales force may
not be developed as contemplated and that one or more of Vicuron's product
candidates may not be commercialized successfully. The reports that Vicuron
files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward- looking statements. The information set forth in this news release
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release. 

DATASOURCE: Vicuron Pharmaceuticals Inc.



CONTACT:  Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,

[phone], or ; or E. Blair Schoeb of WeissComm

Partners, [phone], or , or Heather May of

Burns McClellan Inc., [phone], or , both for Vicuron

Pharmaceuticals Inc.



Web site:  http://www.vicuron.com/ 

Copyright